Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Ian H de BoerUniversity of Washington, Seattle, Washington. Electronic address: deboer@u.washington.edu.
Maryam AfkarianUniversity of Washington, Seattle, Washington.
Katherine R TuttleUniversity of Washington, Providence Health Care, Spokane, Washington.
Funding
Transform Dissemination and Implementation Science in CTSA ProgramsUL1TR002319 · NCATS · UNIVERSITY OF WASHINGTON · PI John K. Amory · 2017 to 2026
$100.0M
Institute of Translational Health SciencesUL1TR000423 · NCATS · UNIVERSITY OF WASHINGTON · PI DISIS, MARY L. · 2012 to 2016
$49.4M
PERL: A multicenter clinical trial of allopurinol to prevent GFR loss in T1DUC4DK101108 · NIDDK · JOSLIN DIABETES CENTER · PI DORIA, ALESSANDRO, MAUER, S. MICHAEL · 2013 to 2018
$31.6M
Training Program in Clinical & Translationa Research in Human Glomerular DiseaseU54DK083912 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GIPSON, DEBBIE S · 2009 to 2023
$20.3M
CORAL: Clinical Coordinating CenterU01HL071556 · NHLBI · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI COOPER, CHRISTOPHER J · 2004 to 2013
$19.3M
Primary Outcomes in Glomerulonephritis Study (PROGRESS)UM1DK100846 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI HOLZMAN, LAWRENCE B. · 2013 to 2018
$5.8M
Randomized trial of vitamin D and omega-3 fatty acids for diabetic kidney diseaseR01DK088762 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2019
$4.7M
Vitamin D Catabolism in Chronic Kidney DiseaseR01DK099199 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2014 to 2018
$3.2M
Oxidative Stress in Chronic Kidney DiseaseR01HL070938 · NHLBI · UNIVERSITY OF WASHINGTON · PI HIMMELFARB, JONATHAN, IKIZLER, TALAT ALP · 2003 to 2012
$3.2M
Insulin Resistance in Chronic Kidney DiseaseR01DK087726 · NIDDK · UNIVERSITY OF WASHINGTON · PI DE BOER, IAN H · 2010 to 2013
$1.9M
Molecular signatures of diabetic kidney diseaseR01DK104706 · NIDDK · UNIVERSITY OF WASHINGTON · PI AFKARIAN, MARYAM · 2015 to 2017
$1.3M
Identifying urinary biomarkers for early type 2 diabetic nephropathyK23DK089017 · NIDDK · UNIVERSITY OF WASHINGTON · PI AFKARIAN, MARYAM · 2010 to 2014
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Surging Tide of Diabetes: Implications for Nephrology. · full record | OpenQuestion